...
【24h】

Familial Pancreatic Cancer

机译:家族性胰腺癌

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Approximately 5% to 10% of individuals with pancreatic cancer report a history of pancreatic cancer in a close family member. In addition, several known genetic syndromes, such as familial breast cancer (BRCA2), the Peutz-Jeghers syndrome, and the familial atypical multiple mole melanoma syndrome, have been shown to be associated with an increased risk of pancreatic cancer. The known genes associated with these conditions can explain only a portion of the clustering of pancreatic cancer in families, and research to identify additional susceptibility genes is ongoing. OBJECTIVE: To provide an understanding of familial pancreatic cancer and the pathology of familial exocrine pancreatic cancers. DATA SOURCES: Published literature on familial aggregation of pancreatic cancer and familial exocrine pancreatic tumors. CONCLUSIONS: Even in the absence of predictive genetic testing, the collection of a careful, detailed family history is an important step in the management of all patients with pancreatic cancer. While most pancreatic cancers that arise in patients with a family history are ductal adenocarcinomas, certain subtypes of pancreatic cancer have been associated with familial syndromes. Therefore, the histologic appearance of the pancreatic cancer itself, and/or the presence and appearance of precancerous changes in the pancreas, may increase the clinical index of suspicion for a genetic syndrome.
机译:背景:约有5%至10%的胰腺癌患者有近亲家属有胰腺癌病史。此外,已显示出几种已知的遗传综合征,例如家族性乳腺癌(BRCA2),Peutz-Jeghers综合征和家族性非典型多发性黑素瘤综合征,与胰腺癌的风险增加相关。与这些疾病相关的已知基因只能解释家族中胰腺癌的一部分,目前正在进行有关鉴定其他易感基因的研究。目的:了解家族性胰腺癌和家族性外分泌胰腺癌的病理学。数据来源:有关胰腺癌的家族聚集和家族外分泌胰腺肿瘤的已发表文献。结论:即使没有预测性的基因检测,收集仔细,详细的家族史也是所有胰腺癌患者治疗的重要步骤。家族史患者中出现的大多数胰腺癌是导管腺癌,但某些胰腺癌亚型与家族综合症有关。因此,胰腺癌本身的组织学外观和/或胰腺癌前变化的存在和外观可能会增加对遗传综合征的怀疑的临床指数。

著录项

  • 来源
    《Archives of Pathology & Laboratory Medicine》 |2009年第3期|p.365-374|共10页
  • 作者单位

    Chanjuan Shi, MD, PhD, Ralph H. Hruban, MD, Alison P. Klein, PhDAccepted for publication October 8, 2008.From the Departments of Pathology (Drs Shi, Hruban, and Klein) and Oncology (Drs Hruban and Klein), The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University, Baltimore, Maryland, and the Department of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland (Dr Klein).The authors have no relevant financial interest in the products or companies described in this article.Reprints: Alison P. Klein, PhD, Departments of Oncology and Pathology, The Johns Hopkins School of Medicine, 1550 Orleans St, Room 303, Baltimore, MD 21212 (e-mail: aklein1@jhmi.edu).,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号